Xtx Topco LTD Fate Therapeutics Inc Transaction History

Xtx Topco LTD

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$3.26 - $7.08 $53,822 - $116,890	16,510 Added 94.95%	33,898 $111,000
Q1 2024 May 13, 2024	BUY	$3.54 - $8.35 $61,553 - $145,189	17,388 New	17,388 $127,000
Q3 2023 Nov 13, 2023	BUY	$2.02 - $5.04 $346,068 - $863,457	171,321 Added 793.19%	192,920 $408,000
Q2 2023 Aug 14, 2023	SELL	$4.76 - $6.59 $31,373 - $43,434	-6,591 Reduced 23.38%	21,599 $102,000
Q1 2023 May 12, 2023	SELL	$4.24 - $11.12 $322,240 - $845,119	-76,000 Reduced 72.94%	28,190 $160,000
Q4 2022 Feb 14, 2023	BUY	$9.86 - $23.83 $824,986 - $1.99 Million	83,670 Added 407.75%	104,190 $1.05 Million
Q3 2022 Nov 14, 2022	BUY	$21.04 - $36.06 $431,740 - $739,951	20,520 New	20,520 $460,000
Q3 2021 Nov 12, 2021	SELL	$59.27 - $95.73 $298,661 - $482,383	-5,039 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$67.25 - $92.52 $338,872 - $466,208	5,039 New	5,039 $437,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Xtx Topco LTD, based on Form 13F filings with the SEC.

Stay updated on Xtx Topco LTD with notifications on news.